SK pharmteco, a Rancho Cordova, California-based CDMO of small-molecule active pharmaceutical ingredients and cell and gene therapies, has announced an investment of $260 million to construct a new facility in Sejong, South Korea, to support its small-molecule and peptide production capabilities. 

Scheduled to begin operations in late 2026, the new facility will be the company’s fifth plant in South Korea. Spanning 135,800 square feet, it will feature eight production trains with an output of tens of metric tons annually. This investment also includes peptide R&D facilities, cGMP kilo labs, and a cGMP pilot plant for peptide manufacturing. The investment also includes building the shell for a sixth manufacturing plant, which will allow a quick expansion of capacity in the future. 

SK pharmteco says it plans to hire over 300 new employees at the Sejong site to support this expansion. 

Source: SK pharmteco